1. Home
  2. SIBN vs ZYME Comparison

SIBN vs ZYME Comparison

Compare SIBN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SIBN
  • ZYME
  • Stock Information
  • Founded
  • SIBN 2008
  • ZYME 2003
  • Country
  • SIBN United States
  • ZYME United States
  • Employees
  • SIBN N/A
  • ZYME N/A
  • Industry
  • SIBN Medical/Dental Instruments
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • SIBN Health Care
  • ZYME Health Care
  • Exchange
  • SIBN Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • SIBN 733.0M
  • ZYME 867.6M
  • IPO Year
  • SIBN 2018
  • ZYME 2017
  • Fundamental
  • Price
  • SIBN $17.25
  • ZYME $13.33
  • Analyst Decision
  • SIBN Strong Buy
  • ZYME Buy
  • Analyst Count
  • SIBN 5
  • ZYME 7
  • Target Price
  • SIBN $24.40
  • ZYME $19.50
  • AVG Volume (30 Days)
  • SIBN 345.1K
  • ZYME 490.0K
  • Earning Date
  • SIBN 08-04-2025
  • ZYME 08-07-2025
  • Dividend Yield
  • SIBN N/A
  • ZYME N/A
  • EPS Growth
  • SIBN N/A
  • ZYME N/A
  • EPS
  • SIBN N/A
  • ZYME N/A
  • Revenue
  • SIBN $176,601,000.00
  • ZYME $93,384,000.00
  • Revenue This Year
  • SIBN $19.48
  • ZYME $44.71
  • Revenue Next Year
  • SIBN $16.86
  • ZYME $34.57
  • P/E Ratio
  • SIBN N/A
  • ZYME N/A
  • Revenue Growth
  • SIBN 22.60
  • ZYME 85.05
  • 52 Week Low
  • SIBN $11.70
  • ZYME $9.03
  • 52 Week High
  • SIBN $20.05
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • SIBN 46.79
  • ZYME 49.83
  • Support Level
  • SIBN $16.39
  • ZYME $13.98
  • Resistance Level
  • SIBN $17.82
  • ZYME $15.00
  • Average True Range (ATR)
  • SIBN 0.62
  • ZYME 0.59
  • MACD
  • SIBN -0.02
  • ZYME -0.01
  • Stochastic Oscillator
  • SIBN 34.68
  • ZYME 25.11

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: